Vildagliptin oral tablets, DPP-4 inhibitors, formulated for type 2 diabetes glycemic control. Produced by pharmaceutical entities and channeled to wholesalers, retail outlets, and healthcare institutions. Acquired by clinicians in diabetes centers and general hospitals for routine patient therapy.